Valneva posts modest FY25 revenue gain as proprietary vaccines offset third-party decline
Valneva reported FY25 revenues of €174.7 million, a slight increase from €169.6 million the prior year, driven in part by variable consideration recognized under its Lyme disease collaboration. While product sales fell 3.3% to €157.9 million because third-party distribution dropped 42% to €19.2 million, the company’s proprietary portfolio (excludin…